Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
1999-09-28
2001-06-05
Hartley, Michael G. (Department: 1619)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C546S210000, C546S223000, C435S007100, C436S804000
Reexamination Certificate
active
06241964
ABSTRACT:
BACKGROUND OF THE INVENTION
Noninvasive, nuclear imaging techniques can be used to obtain basic and diagnostic information about the physiology and biochemistry of a variety of living subjects including experimental animals, normal humans and patients. These techniques rely on the use of sophisticated imaging instrumentation which is capable of detecting radiation emitted from radiotracers administered to such living subjects. The information obtained can be reconstructed to provide planar and tomographic images which reveal distribution of the radiotracer as a function of time. Use of appropriately designed radiotracers can result in images which contain information on the structure, function and most importantly, the physiology and biochemistry of the subject. Much of this information cannot be obtained by other means. The radiotracers used in these studies are designed to have defined behaviors in vivo which permit the determination of specific information concerning the physiology or biochemistry of the the subject or the effects that various diseases or drugs have on the physiology or biochemistry of the subject. Currently, radiotracers are available for obtaining useful information concerning such things as cardiac function, myocardial blood flow, lung perfusion, liver function, brain blood flow, regional brain glucose and oxygen metabolism.
Compounds can be labeled with either positron or gamma emitting radionuclides. For imaging, the most commonly used positron emitting (PET) radionuclides are
11
C,
18
F,
15
O and
13
N, all of which are accelerator produced, and have half lifes of 20, 110, 2 and 10 min. respectively. Since the half-lives of these radionuclides are so short, it is only feasible to use them at institutions which have an accelerator on site for their production, thus limiting their use. Several gamma emitting radiotracers are available which can be used by essentially any hospital in the U.S. and in most hospitals worldwide. The most widely used of these are
18
F,
99m
Tc,
201
TI and
123
I.
In the past decade, one of the most active areas of nuclear medicine research has been the development of receptor imaging radiotracers. These tracers bind with high affinity and specificity to selective hormone receptors and neuroreceptors. Successful examples include radiotracers for imaging the following receptor systems: estrogen, muscarinic, dopamine D1 and D2, and opiate.
The neuropeptide receptors for substance P (neurokinin-1; NK-1) are widely distributed throughout the mammalian nervous system (especially brain and spinal ganglia), the circulatory system and peripheral tissues (especially the duodenum and jejunum) and are involved in regulating a number of diverse biological processes. This includes sensory perception of olfaction, vision, audition and pain, movement control, gastric motility, vasodilation, salivation, and micturition (B. Pernow,
Pharmacol. Rev
., 1983, 35, 85-141). The NK-1 and NK-2 receptor subtypes are implicated in synaptic transmission (Laneuville et al.,
Life Sci
., 42: 1295-1305 (1988)). The receptor for substance P is a member of the superfamily of G protein-coupled receptors. This superfamily is an extremely diverse group of receptors in terms of activating ligands and biological functions.
Substance P (also called “SP” herein) is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt contractile action on extravascular smooth muscle tissue. In addition to SP the known mammalian tachykinins include neurokinin A and neurokinin B. The current nonmenclature designates the receptors for SP, neurokinin A, and neurokinin B as NK-1, NK-2, and NK-3, respectively. Neurokinin-1 (NK-1; substance P) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins, and in particular substance P. Substance P has been implicated in gastrointestinal (GI) disorders and diseases of the GI tract, such as emesis [
Trends Pharmacol. Sci
., 9, 334-341 (1988), F. D. Tatersall, et al.,
Eur. J. Pharmacol
., 250, R5-R6 (1993)], and in psychiatric disorders, such as depression (Kramer, et al.,
Science
, 281, 1640-1645 (Sep. 11, 1998). The compound [2-fluoromethoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-([2S,3S]-2-phenyl-piperidin-3-yl)-amine is disclosed in PCT Patent Publication WO 96/21661 as a tachykinin antagonist.
PET (Positron Emission Tomography) radiotracers and imaging technology may provide a powerful method for clinical evaluation and dose selection of neurokinin-1 receptor antagonists. Using a fluorine-18 or carbon-11 labeled radiotracer that provides a neurokinin-1 receptor-specific image in the brain and other tissues, the dose required to saturate neurokinin-1 receptors can be determined by the blockade of the PET radiotracer image in humans. The rationale for this approach is as follows: efficacy of a neurokinin-1 receptor antagonist is a consequence of the extent of receptor inhibition, which in turn is a function of the degree of drug-receptor occupancy.
It is, therefore, an object of this invention to develop radiolabeled neurokinin-1 receptor antagonists that would be useful not only in traditional exploratory and diagnostic imaging applications, but would also be useful in assays, both in vitro and in vivo, for labeling the neurokinin-1 receptor and for competing with unlabeled neurokinin-1 receptor antagonists and agonists. It is a further object of this invention to develop novel assays which comprise such radiolabeled compounds.
SUMMARY OF THE INVENTION
The present invention is directed to certain radiolabeled neurokinin-1 receptor antagonists. The present invention is further concerned with methods for the use of such radiolabeled neurokinin-1 receptor antagonists for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to certain radiolabeled neurokinin-1 receptor antagonists. In particular, the present invention is directed to a compound of the formula:
wherein:
R
1
is a radionuclide selected from the group consisting of:
3
H,
11
C,
18
F,
125
I,
82
Br,
123
I,
131
I,
75
Br,
15
O,
13
N,
211
At and
77
Br;
and pharmaceutically acceptable salts thereof.
In a preferred embodiment of the present invention R
1
is
11
C or
18
F.
In a more preferred embodiment of the present invention R
1
is
18
F.
In an even more preferred embodiment the present invention is directed to the compound
[
18
F][2-fluoromethoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzy]-([2S,3S]-2-phenyl-piperidin-3-yl)-amine
which may be depicted as:
The present invention is also directed to a radiopharmaceutical composition which comprises a compound of the present invention and at least one pharmaceutically acceptable carrier or excipient.
The present invention is also directed to a method for labeling neurokinin-1 receptors in a mammal which comprises administering to a mammal in need of such labeling an effective amount of the radiolabeled compound of the present invention.
The present invention is also directed to a method for diagnostic imaging of neurokinin-1 receptors in a mammal which comprises administering to a mammal in need of such diagnostic imaging an effective amount of the radiolabeled compound of the present invention.
The present invention is also directed to a method for diagnostic imaging of tissues bearing neurokinin-1 receptors in a mammal which comprises administering to a mammal in need of such diagnostic imaging an effective amount of the radiolabeled compound of the present invention.
The present invention is also directed to a method for the diagnostic imaging of substance P binding sites in tissues of a mammalian species which comprises administering to the mammalian species in need of such diagnostic imaging an effective amount of the radiolabeled compound of the present invention.
The present invention i
Burns H. Donald
Gibson Raymond E.
Hamill Terence G.
Hartley Michael G.
Merck & Co. , Inc.
Rose David L.
Thies J. Eric
LandOfFree
F-18 radiolabeled neurokinin-1 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with F-18 radiolabeled neurokinin-1 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and F-18 radiolabeled neurokinin-1 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2459408